NASDAQ:VRAYViewray Stock Price, Forecast & News

$1.83

-0.04 (-2.14 %)

(As of 05/28/2020 04:00 PM ET)

Add

Compare

Today's Range

$1.83

Now: $1.83▼

$1.92

50-Day Range

$1.66

MA: $2.13▼

$2.73

52-Week Range

$1.11

Now: $1.83▼

$9.76

Volume836,605 shs

Average Volume1.56 million shs

Market Capitalization$269.74 million

P/E RatioN/A

Dividend YieldN/A

Beta0.79

ViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

Beat the Market (BTM) Rank^™

4.3 Analyst's Opinion

Consensus Rating
Viewray has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $5.17, Viewray has a potential upside of 182.3% from its current price of $1.83.
Amount of Analyst Coverage
Viewray has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
Viewray has received 272 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Viewray has received 216 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Viewray has received 55.74% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote “Outperform” if you believe VRAY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Viewray does not currently pay a dividend.
Dividend Growth
Viewray does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Viewray insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 15.48% of the stock of Viewray is held by insiders.
Percentage Held by Institutions
87.36% of the stock of Viewray is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Viewray are expected to remain at ($0.67) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Viewray is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Viewray is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Viewray has a P/B Ratio of 1.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.61 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Electromedical equipment

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:VRAY

Previous Symbol

CUSIPN/A

CIK1597313

Webwww.viewray.com

Phone440-703-3210

Debt

Debt-to-Equity Ratio0.27

Current Ratio4.81

Quick Ratio3.87

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$87.78 million

Price / Sales3.07

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.32 per share

Price / Book1.39

Profitability

EPS (Most Recent Fiscal Year)($1.18)

Net Income$-120,200,000.00

Net Margins-139.91%

Return on Equity-71.37%

Return on Assets-38.95%

Miscellaneous

EmployeesN/A

Outstanding Shares147,400,000

Market Cap$269.74 million

Next Earnings Date8/13/2020 (Estimated)

OptionableOptionable

Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter.

Viewray (NASDAQ:VRAY) Frequently Asked Questions

How has Viewray's stock been impacted by COVID-19 (Coronavirus)?

Viewray's stock was trading at $1.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VRAY stock has increased by 8.3% and is now trading at $1.83. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Viewray?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Viewray.

When is Viewray's next earnings date?

Viewray is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Viewray.

How were Viewray's earnings last quarter?

Viewray Inc (NASDAQ:VRAY) posted its earnings results on Thursday, April, 30th. The company reported ($0.19) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.19). The company had revenue of $14.25 million for the quarter, compared to analysts' expectations of $12.47 million. Viewray had a negative return on equity of 71.37% and a negative net margin of 139.91%. View Viewray's earnings history.

What guidance has Viewray issued on next quarter's earnings?

Viewray updated its FY 2020 After-Hours earnings guidance on Thursday, March, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $58-95 million, compared to the consensus revenue estimate of $110.15 million.

What price target have analysts set for VRAY?

10 brokerages have issued 1 year target prices for Viewray's stock. Their forecasts range from $2.00 to $8.00. On average, they anticipate Viewray's stock price to reach $5.17 in the next twelve months. This suggests a possible upside of 182.3% from the stock's current price. View analysts' price targets for Viewray.

Has Viewray been receiving favorable news coverage?

News coverage about VRAY stock has been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Viewray earned a media sentiment score of 0.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the near term. View the latest news aboutViewray.

Who are some of Viewray's key competitors?

Some companies that are related to Viewray include InMode (INMD), Natus Medical (NTUS), Zynex (ZYXI), AxoGen (AXGN), BioLife Solutions (BLFS), TransMedics Group (TMDX), Stereotaxis (STXS), BioSig Technologies (BSGM), Semler Scientific (SMLR), Cutera (CUTR), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP), Fc Global Realty (FCRE) and electroCore (ECOR). View all competitors.

What other stocks do shareholders of Viewray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Crispr Therapeutics (CRSP), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), Verastem (VSTM), Anavex Life Sciences (AVXL) and Inovio Pharmaceuticals (INO).

When did Viewray IPO?

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is Viewray's stock symbol?

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

Who are Viewray's major shareholders?

Viewray's stock is owned by a variety of institutional and retail investors. Top institutional investors include Hudson Executive Capital LP (8.84%), BlackRock Inc. (4.88%), Silvercrest Asset Management Group LLC (2.63%), State Street Corp (1.35%), Geode Capital Management LLC (1.07%) and Needham Investment Management LLC (0.75%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View institutional ownership trends for Viewray.

Which major investors are selling Viewray stock?

VRAY stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, Bank of New York Mellon Corp, JPMorgan Chase & Co., Morgan Stanley, Ieq Capital LLC, Joel Isaacson & Co. LLC, Weiss Multi Strategy Advisers LLC, and Essex Investment Management Co. LLC. View insider buying and selling activity for Viewray.

Which major investors are buying Viewray stock?

VRAY stock was bought by a variety of institutional investors in the last quarter, including Hudson Executive Capital LP, BlackRock Inc., Needham Investment Management LLC, Silvercrest Asset Management Group LLC, State Street Corp, Geode Capital Management LLC, UBS Group AG, and Nuveen Asset Management LLC. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake, and Shahriar Matin. View insider buying and selling activity for Viewray.

How do I buy shares of Viewray?

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Viewray's stock price today?

One share of VRAY stock can currently be purchased for approximately $1.83.

How big of a company is Viewray?

Viewray has a market capitalization of $269.74 million and generates $87.78 million in revenue each year. The company earns $-120,200,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

What is Viewray's official website?

The official website for Viewray is www.viewray.com.

How can I contact Viewray?

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff